{"id":10290,"date":"2025-03-07T15:05:24","date_gmt":"2025-03-07T06:05:24","guid":{"rendered":"https:\/\/www.wakakoukai.or.jp\/daiichi\/?page_id=10290"},"modified":"2025-12-19T11:38:34","modified_gmt":"2025-12-19T02:38:34","slug":"kenkyu-ketsunai","status":"publish","type":"page","link":"https:\/\/www.wakakoukai.or.jp\/daiichi\/overview\/byouin-shihyo\/kenkyu\/kenkyu-ketsunai\/","title":{"rendered":"\u8840\u6db2\u5185\u79d1\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"

<\/a><\/p>\r\n

2025\u5e74<\/h2>\r\n

1.\u5b66\u4f1a\u767a\u8868\u7b49<\/h3>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
1-1<\/td>\r\nYusuke Okayama : Complement involvements and issues in TA-TMA after allogeneic hematopoietic cell transplantation, \u7b2c47\u56de\u65e5\u672c\u9020\u8840\u30fb\u514d\u75ab\u7d30\u80de\u7642\u6cd5\u5b66\u4f1a\u7dcf\u4f1a, 2025.02.27-03.01<\/td>\r\n<\/tr>\r\n
1-2<\/td>\r\n\u7d30\u4e95\u60a0\u4ecb, \u9ad8\u6851\u8f1d\u4eba, \u5ca1\u5c71\u88d5\u4ecb, \u798f\u5c71\u667a\u5b50 : EDTA \u975e\u4f9d\u5b58\u6027\u8840\u5c0f\u677f\u51dd\u96c6\u306b\u304a\u3044\u3066EDTA \u904e\u5270\u6dfb\u52a0\u63a1\u8840\u7ba1\u304c\u6709\u7528\u3067\u3042\u308b\u53ef\u80fd\u6027, \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u691c\u67fb\u5b66\u4f1a, 2025.05.10-11<\/td>\r\n<\/tr>\r\n
1-3<\/td>\r\n\u9ad9\u6851\u8f1d\u4eba : \u95a2\u897f\u9aa8\u9ac4\u816b\u30d5\u30a9\u30fc\u30e9\u30e0\uff08KMF\uff0913\u5e74\u306e\u8ecc\u8de1, \u7b2c50\u56de\u65e5\u672c\u9aa8\u9ac4\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.05.23-25<\/td>\r\n<\/tr>\r\n
1-4<\/td>\r\n\u9ad9\u6851\u8f1d\u4eba ,\u5800\u7530 \u96c5\u7ae0 , \u85e4\u7530 \u771f\u4e5f, \u5fd7\u6751 \u52c7\u53f8, \u82b1\u672c \u4ec1, \u5409\u539f \u54f2, \u82b9\u6fa4 \u61b2\u592a\u90ce, \u6df5\u7530 \u771f\u4e00, \u677e\u672c \u5fe0\u5f66, \u8aeb\u7530 \u6df3\u4e5f, \u6cb3\u7530 \u82f1\u91cc, \u4e00\u4e95 \u502b\u5b50, \u798f\u5cf6 \u5065\u592a\u90ce, \u4f0a\u85e4 \u91cf\u57fa, \u9ed2\u7530 \u7d14\u4e5f, \u677e\u6751 \u5230, \u5cf6\u5d0e \u5343\u5c0b, \u9ad8\u6298 \u6643\u53f2, \u65e5\u91ce \u96c5\u4e4b, \u4fdd\u4ed9 \u76f4\u6bc5 : NDMM\u306e\u814e\u6a5f\u80fd\u3068\u4e88\u5f8c\u3078\u306e\u5bc4\u4e0e\u5ea6 -\u95a2\u897f\u9aa8\u9ac4\u816b\u30d5\u30a9\u30fc\u30e9\u30e0\u5f8c\u65b9\u8996\u7684\u7814\u7a76-, \u7b2c50\u56de\u65e5\u672c\u9aa8\u9ac4\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.05.23-25<\/td>\r\n<\/tr>\r\n
1-5<\/td>\r\nTomoaki Fujisaki , Kohmei Kubo, Yasushi Hiramatsu, Ryosuke Ogawa, Shinsuke Iida, Takashi Ikeda, Hiromi Iwasaki, Shingo Kurahashi, Morio Matsumoto, Tomonori Nakazato, Kazutaka Sunami, Teruhito Takakuwa, Yotaro Tamai, Kazuki Tanimoto, Junichi Tsukada, Ryosuke Yamamura, Taku Fujii, Akira Endo, Hirofumi Nakano, Joe Lee : Belantamab mafodotin, bortezomib, dexamethasone for RRMM: the DREAMM-7 Japanese expansion cohort, \u7b2c50\u56de\u65e5\u672c\u9aa8\u9ac4\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.05.23-25<\/td>\r\n<\/tr>\r\n
1-6<\/td>\r\n\u5ca1\u5c71\u88d5\u4ecb ,\u8c37\u6fa4\u76f4, \u76f8\u672c\u745e\u6a39, \u5e73\u4e95\u5b66, \u592a\u7530\u5065\u4ecb, \u9ad9\u6851\u8f1d\u4eba : \u5f53\u9662\u306b\u304a\u3051\u308b\u518d\u767a\u96e3\u6cbb\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u5bfe\u3059\u308belranatamab\u306e\u4f7f\u7528\u7d4c\u9a13, \u7b2c50\u56de\u65e5\u672c\u9aa8\u9ac4\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.05.23-25<\/td>\r\n<\/tr>\r\n
1-7<\/td>\r\nHang Quach , Bradley Augustson, Linda Barton, Edvan de Queiroz Crusoe, Jeffrey S.Y. Huang, Vania Hungria, Marek Hus, Karthik Ramasamy, Teruhito Takakuwa, Dok Hyun Yoon, Rupam Pal, Shreyan Banerjee, Hari Narayan, Wei Sun, Malika Ahras, Seema Shafi-Harji, Sarantos Kaptanis, Giulia Fulci, Brandon Kremer, and Chang-Ki Min : Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1\/2 DREAMM-20 trial, ASCO(American Society of Clinical Oncology) Annual Meeting, 2025.05.30-06.03<\/td>\r\n<\/tr>\r\n
1-8<\/td>\r\nHang Quach , Bradley Augustson, Linda Barton, Edvan Crusoe, Jeffrey Huang, Vania Hungria, Marek Hus, Karthik Ramasamy, Teruhito Takakuwa, Dok Hyun Yoon, Elisabet Manasanch, John Clements, Xiangdong Zhou, Rupam Pal, Shreyan Banerjee, Hari Narayan, Wei Sun, Malika Ahras, Seema Shafi-harji, Sarantos Kaptanis, Giulia Fulci, Brandon E. Kremer, Chang-Ki Mi :BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: RESULTS FROM PART 1 OF THE FIRST-IN-HUMAN PHASE 1\/2 DREAMM-20 TRIAL, 30th EHA(European Hematology Association) Congress, 2025.06.12-15<\/td>\r\n<\/tr>\r\n
1-9<\/td>\r\n\u718a\u8c37\u7dbe\u592a, \u7389\u6751\u60a0\u4ecb, \u677e\u6d66\u9053\u5b50, \u671d\u5ddd\u5f18\u7ae0, \u5ca1\u5c71\u88d5\u4ecb, \u9ad9\u6851\u8f1d\u4eba : \u9020\u8840\u5668\u816b\u760d\u60a3\u8005\u306e\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u63d0\u4f9b\u4f53\u5236\u306e\u69cb\u7bc9\u306b\u5411\u3051\u305f\u6cd5\u4eba\u5185\u65bd\u8a2d\u9593\u9023\u643a, \u7b2c75\u56de\u65e5\u672c\u75c5\u9662\u5b66\u4f1a, 2025.07.24-25<\/td>\r\n<\/tr>\r\n
1-10<\/td>\r\n\u7d30\u4e95\u60a0\u4ecb, \u5ca1\u5c71\u88d5\u4ecb\u3001\u798f\u5c71\u667a\u5b50\u3001\u9ad8\u6851\u8f1d\u4eba : \u82bd\u7403\u306b\u5e7c\u82e5\u8d64\u82bd\u7403\u6297\u539f\u3092\u767a\u73fe\u3057\u305f\u9aa8\u9ac4\u7570\u5f62\u6210\u95a2\u9023\u5909\u5316\u3092\u4f34\u3046\u6025\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\uff08AML-MR\uff09\u306e\u4e00\u4f8b, \u7b2c26\u56de\u65e5\u672c\u691c\u67fb\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.07.26-27<\/td>\r\n<\/tr>\r\n
1-11<\/td>\r\n\u65e5\u91ce \u96c5\u4e4b, : \u540c\u7a2e\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u306e\u9032\u5316\u3068\u5c06\u6765\u5c55\u671b, \u7b2c33\u56de\u65e5\u672c\u7d44\u7e54\u9069\u5408\u6027\u5b66\u4f1a\u5927\u4f1a, 2025.10.03-05<\/td>\r\n<\/tr>\r\n
1-12<\/td>\r\nKentaro Serizawa, Masaaki Hotta, Shinya Fujita, Yuji Shimura, Tadahiko Matsumoto, Junya Kanda, Satoshi Yoshihara, Shin-ichi Fuchida, Eri Kawata, Hitoshi Hanamoto, Michiko Ichii, Kentaro Fukushima, Yosuke Nakaya, Teruhito Takakuwa, Tomoki Ito, Junya Kuroda, Akifumi Takaori-Kondo, Chihiro Shimazaki, Masayuki Hino, Itaru Matsumura, Naoki Hosen :Real-world efficacy of isatuximab, carfilzomib, and dexamethasone in RRMM: KMF database analysis, \u7b2c87\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.10.10-12<\/td>\r\n<\/tr>\r\n
1-13<\/td>\r\nTakahiro Sunano, Yusuke Okayama, Yusuke Tanada, Masayuki Hino, Teruhito Takakuwa :Real-world efficacy of isatuximab, carfilzomib, and dexamethasone in RRMM: An autopsy case of CPX-351-resistant AML-MR with immature erythroid antigen positivity, \u7b2c87\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.10.10-12<\/td>\r\n<\/tr>\r\n
1-14<\/td>\r\nYusuke Tanada, Yusuke Okayama, Masayuki Hino, Teruhito Takakuwa :Colitis as an immune-related adverse event of elranatamab in a refractory plasma cell leukemia, \u7b2c87\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.10.10-12<\/td>\r\n<\/tr>\r\n
1-15<\/td>\r\n\u52a0\u85e4\u771f\u7531\u7f8e, \u4eca\u5800\u53cb\u7d00, \u68da\u7530\u60a0\u4ecb, \u5ca1\u5c71\u88d5\u4ecb, \u5c71\u4e2d\u82f1\u6cbb, \u65e5\u91ce\u96c5\u4e4b, \u9ad9\u6851\u8f1d\u4eba :\u9020\u8840\u5668\u816b\u760d\u9818\u57df\u306e\u5316\u5b66\u7642\u6cd5\u3092\u62c5\u3046\u85ac\u5264\u5e2b\u306b\u3088\u308b\u30d1\u30b9\u4f5c\u6210\u3068\u904b\u7528\u8a55\u4fa1, \u7b2c25\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a, 2025.10.17-18<\/td>\r\n<\/tr>\r\n
1-16<\/td>\r\n\u9ad9\u6851\u8f1d\u4eba, \u591a\u7530\u96c4\u771f, \u4e2d\u820e\u6d0b\u8f14, \u592a\u7530\u5065\u4ecb, \u5c0f\u66fd\u6839\u5357\u7f8e, \u5c71\u672c\u85ab, \u4e2d\u524d\u535a\u4e45, \u65e5\u91ce\u96c5\u4e4b, \u6a2a\u7530\u8cb4\u53f2 :\u9020\u8840\u5668\u816b\u760d\u306b\u304a\u3051\u308b\u5730\u57df\u533b\u7642\u9023\u643a\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u69cb\u7bc9\u3068\u6d3b\u7528, \u7b2c25\u56de\u65e5\u672c\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u533b\u5b66\u4f1a\u79cb\u5b63\u5b66\u8853\u96c6\u4f1a, 2025.10.17-18<\/td>\r\n<\/tr>\r\n
1-17<\/td>\r\n\u718a\u8c37\u7dbe\u592a, \u7389\u6751\u60a0\u4ecb, \u7c73\u8c37\u6b63\u6a39, \u9ad9\u6851\u8f1d\u4eba :\u8840\u6db2\u816b\u760d\u60a3\u8005\u306b\u304a\u3051\u308b\u9000\u9662\u6642ADL\u3068\u8eab\u4f53\u304a\u3088\u3073\u547c\u5438\u6a5f\u80fd\u3068\u306e\u95a2\u9023, \u7b2c9\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a, 2025.10.23-25<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n

<\/a><\/p>\r\n

2024\u5e74<\/h2>\r\n

1.\u5b66\u4f1a\u767a\u8868\u7b49<\/h3>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
1-1<\/td>\r\n\u9ad8\u6851\u8f1d\u4eba,\u5ca1\u5c71\u88d5\u4ecb,\u5c71\u4e2d\u82f1\u6cbb: \u300c\u8840\u6db2\u9023\u643a\u30d1\u30b9\u300d\u3092\u6d3b\u7528\u3057\u305f\u62e0\u70b9\u75c5\u9662\u3068\u5730\u57df\u533b\u7642\u3068\u306e\u6a4b\u6e21\u3057, \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u611b\u5a9b, 2024.10.04-05(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-2<\/td>\r\n\u52a0\u85e4 \u771f\u7531\u7f8e,\u4e2d\u7530 \u6566\u5b50, \u5e73\u6adb \u5b9f\u7a42, \u4e0a\u7530 \u5c55\u4ee3, \u91ce\u53e3 \u667a\u6075\u5b50, \u5c71\u672c \u76f4\u7f8e, \u4eca\u7530 \u5149\u4e00, \u5c71\u4e2d \u82f1\u6cbb, \u5ca1\u5c71 \u88d5\u4ecb, \u9ad8\u6851 \u8f1d\u4eba:\u96fb\u5b50\u30ab\u30eb\u30c6\u30d9\u30f3\u30c0\u30fc\u5909\u66f4\u3068\u96fb\u5b50\u30d1\u30b9\u5c0e\u5165\u306b\u304a\u3051\u308b\u85ac\u5264\u5e2b\u306e\u95a2\u308f\u308a , \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2024.10.04-05<\/td>\r\n<\/tr>\r\n
1-3<\/td>\r\nMitsuhiro Itagaki , Tomoaki Fujisaki, Yoshiaki Ogawa, Teruhito Takakuwa, Anna Sureda Balari, Abdullah Mohammad Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas Rodr\u00edguez, Brea Lipe, Paula Rodr\u00edguez Otero, Jie Pu, Michael Amatangelo, Kexin Jin, Sakiko Kuroda, Thomas Solomon, Lilia Taningco, Alpesh Amin, Paulo Maciag, Sagar Lonia :Iberdomide, daratumumab, and dexamethasone (IberDd) in newly diagnosed multiple myeloma (NDMM) , \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-4<\/td>\r\nTeruhito Takakuwa, Ikue Shiki, Ryosuke Yamamura, Kensuke Ohta, Naoko Yagi, Naonori Harada, Masafumi Fukaya, Kanako Yoshitsugu, Hiroshi Okamura, Taku Araki, Yotaro Fujitani, Mitsutaka Nishimoto, Terukazu Enami, Yasuhiro Nakashima, Takahiko Nakane, Mika Nakamae, Hirohisa Nakamae, Atsuko Mugitani, Takafumi Nakao, Takashi Ikeda, Masayuki Hino :IsaKd versus IsaPd: A multicenter propensity score matched retrospective analysis , \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-5<\/td>\r\nTetsuya Hayashi, Kazuo Tanaka, Daiki Mukai, Yasuhiro Nakashima, Mitsutaka Nishimoto, Hiroshi Okamura, Teruhito Takakuwa, Masatomo Kuno, Yosuke Makuuchi, Kentaro Ido, Kazuki Sakatoku, Mirei Horiuchi, Mika Nakamae, Masayuki Hino, Hirohisa Nakamae :Fulminant delayed toxicity in the gastrointestinal tract after CAR-T cell therapy , \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-6<\/td>\r\nYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shinichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori Kondo, Masayuki Hino :Predicting efficacy of isatuximab + pomalidomide for multiple myeloma by lymphocyte\/monocyte ratio , \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-7<\/td>\r\nMasatomo Kuno, Hideo Koh, Yusuke Okayama, Yukako Yasui, Wataru Shibata, Tsubasa Koyama, Makoto Nishijima, Seidai Tanaka, Yuto Izuta, Daiki Mukai, Mai Kawazoe, Hidekatsu Yae, Nobuhiro Sogabe, Soichiro Nakako, Kumiyo Tazoe, Mirei Horiuchi, Kentaro Ido, Kazuki Sakatoku, Yosuke Makuuchi, Teruhito Takakuwa, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Hiroyuki Yasui, Hiroshi Kakeya, Masayuki Hino, Hirohisa Nakamae : Drug interactions between posaconazole and tacrolimus by route of administration, \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a,\u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-8<\/td>\r\nYusuke Okayama, Hideo Koh, Masatomo Kuno, Yukako Yasui, Wataru Shibata, Tsubasa Koyama, Makoto Nishijima, Seidai Tanaka, Yuto Izuta, Daiki Mukai, Mai Kawazoe, Hidekatsu Yae, Nobuhiro Sogabe, Soichiro Nakako, Kumiyo Tazoe, Mirei Horiuchi, Kentaro Ido, Kazuki Sakatoku, Yosuke Makuuchi, Teruhito Takakuwa, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Hiroyuki Yasui, Hiroshi Kakeya, Masayuki Hino, Hirohisa Nakamae : High day 7 posaconazole concentration is a risk factor for hypokalemia, \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-9<\/td>\r\nHirokazu Tanaka, Atsushi Shinagawa, Kohmei Kubo, Taizo Shimomura, Tatsuro Jo, Akihiko Gotoh, Shuichi Ota, Kensuke Usuki, Kosei Matsue, Miki Ando, Michihiro Uchiyama, Hiroaki Ohnishi, Yoshiaki Ogawa, Yoko Kubuki, Teruhito Takakuwa, Takuji Yamauchi, Kazuo Ito, Mitsufumi Nishio, Go Fujimoto, Akitsugu Takada, Patricia Martin-Regueira, Keita Kirito :Japan phase 1\/2 study of fedratinib in JAK inhibitor pretreated\/-untreated myelofibrosis (MF-003) \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-10<\/td>\r\nMinako Tsutsumi, Teruhito Takakuwa, Makoto Nishijima, Mirei Horiuchi, Yosuke Nakaya, Kazuki Sakatoku, Kentaro Ido, Yosuke Makuuchi, Masatomo Kuno, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Kaori Sakamoto, Chisato Ohe, Kenichi Kohashi, Masayuki Hino, Hirohisa Nakamae : Severe diarrhea as an immune-related adverse event of epcoritamab in two cases of refractory DLBCL, \u7b2c86\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u4eac\u90fd, 2024.10.11-13(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n
1-11<\/td>\r\nTomoki Ito, Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae, Kazunori Murai, Yoko Kubuki, Kazuya Shimoda, Yuji Kumagai, Yukiya Yamamoto, Tadashi Matsuura :Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia,66th ASH Annual Meeting, San Diego,2024.12.07-10(\u30dd\u30b9\u30bf\u30fc\u767a\u8868)<\/td>\r\n<\/tr>\r\n
1-12<\/td>\r\n\u5b89\u4e95\u53cb\u4f73\u5b50\u3001\u5ca1\u5c71\u88d5\u4ecb\u3001\u4e45\u91ce\u96c5\u667a\u3001\u5eb7\u79c0\u7537\u3001\u67f4\u591a\u6e09\u3001\u639b\u5c4b\u5f18\u3001\u5b89\u4e95\u88d5\u4e4b :\u8840\u6db2\u75be\u60a3\u60a3\u8005\u306b\u304a\u3051\u308b\u30dd\u30b5\u30b3\u30ca\u30be\u30fc\u30eb\u306e\u8840\u4e2d\u6fc3\u5ea6\u306b\u5f71\u97ff\u3059\u308b\u907a\u4f1d\u5b50\u591a\u578b\u3092\u542b\u3080\u56e0\u5b50\u89e3\u6790,\u7b2c34\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a,2024.11.02<\/td>\r\n<\/tr>\r\n
1-13<\/td>\r\n\u5ca1\u5c71\u88d5\u4ecb:\u8840\u6db2\u75be\u60a3\u60a3\u8005\u306b\u304a\u3051\u308b\u30dd\u30b5\u30b3\u30ca\u30be\u30fc\u30eb\u306e\u8840\u4e2d\u6fc3\u5ea6\u306b\u5f71\u97ff\u3059\u308b\u907a\u4f1d\u5b50\u591a\u578b\u3092\u542b\u3080\u56e0\u5b50\u89e3\u6790,\u7b2c34\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a, \u5343\u8449,2024.11.03(\u4e00\u822c\u53e3\u6f14)<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n

2.\u5b66\u8853\u8ad6\u6587<\/h3>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
2-1<\/td>\r\nIchiro Shiomi, Yosuke Makuuchi, Ikue Noura, Shigeki Kakuno, Makoto Niki, Yuto Kaimi, Kentaro Ido, Kazuki Sakatoku, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Hiroshi Kakeya, Kenichi Kohashi, Masayuki Hino, Hirohisa Nakamae:Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report,J Infect Chemother. 2024 Jun;30(6):557-561. ,(\u75c7\u4f8b\u5831\u544a)<\/td>\r\n<\/tr>\r\n
2-2<\/td>\r\nMasatomo Kuno, Hideo Koh, Kentaro Ido, Kazuki Sakatoku, Yosuke Makuuchi, Teruhito Takakuwa, Asao Hirose, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Masayuki Hino, Hirohisa Nakamae : Comparison of long-term outcomes after first HLA-mismatched unrelated donor transplantation with single unrelated cord blood transplantation using reduced-intensity or reduced-toxicity conditioning, Transpl Immunol. 2024 Feb:82:101988. ,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-3<\/td>\r\nYusuke Okayama, Naonori Harada, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae : Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission,Int J Hematol. 2024 Mar;119(3):316-326.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-4<\/td>\r\nAsao Hirose, Hideo Koh, Mika Nakamae, Yasuhiro Nakashima, Mitsutaka Nishimoto, Hiroshi Okamura, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Kentaro Ido, Kazuki Sakatoku, Masayuki Hino, Hirohisa Nakamae: A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia\/lymphoma, Bone Marrow Transplant. 2024 May;59(5):695-698.,(Letter)<\/td>\r\n<\/tr>\r\n
2-5<\/td>\r\nKumiyo Tazoe, Naonori Harada, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae: Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia, Ann Hematol. 2024 Jun;103(6):2059-2072.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-6<\/td>\r\nKazuo Fukumoto, Ryu Watanabe, Minako Tsutsumi, Teruhito Takakuwa, Masafumi Miyamoto, Noriyuki Hayashi, Shinsuke Yamada, Yutaka Furumitsu, Masayuki Hino, Motomu Hashimoto: Lymphoproliferative disorder progressing after partial remission following immunosuppressive drugs withdrawal in a patient with rheumatoid arthritis, Mod Rheumatol Case Rep. 2024 Jul 8;8(2):243-248. ,(\u75c7\u4f8b\u5831\u544a)<\/td>\r\n<\/tr>\r\n
2-7<\/td>\r\nMakoto Moriguchi, Kentaro Ido, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Asao Hirose, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae: Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation, Acta Haematol. 2024;147(6):661-670,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-8<\/td>\r\nNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka, Kensuke Ohta, Satoru Kosugi, Hideo Yagi, Satoshi Yoshihara, Ryosuke Yamamura, Yoko Adachi, Hitoshi Hanamoto, Hirohiko Shibayama, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino: Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study,Ann Hematol. 2024 Dec;103(12):5681-5690.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-9<\/td>\r\nKazuya Takemura, Mika Nakamae, Hiroshi Okamura, Kazuki Sakatoku, Kentaro Ido, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Asao Hirose, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Koji Igarashi, Hiroshi Kubota, Masayuki Hino, Hirohisa Nakamae: Autotaxin is a potential predictive marker for the development of veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation, Ann Hematol. 2024 May;103(5):1705-1715,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-10<\/td>\r\nYosuke Makuuchi, Hiroshi Okamura, Yukari Umemoto, Akinori Nishikawa, Rie Tanaka, Akari Sato, Kazuki Sakatoku, Kentaro Ido, Mirei Horiuchi, Masatomo Kuno, Teruhito Takakuwa, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Shingo Yano, Masayuki Hino, Hirohisa Nakamae: Usefulness of web-based application for health surveys before and after peripheral blood stem cell harvest from healthy donors, Rinsho Ketsueki. 2024;65(5):321-329.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-11<\/td>\r\nSoichiro Nakako, Hideo Koh, Nobuhiro Sogabe, Masatomo Kuno, Yosuke Makuuchi, Teruhito Takakuwa, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae: Successful treatment with mesenchymal stem cells for steroid-refractory late-onset idiopathic pneumonia syndrome following allogeneic hematopoietic cell transplantation, Transpl Immunol. 2024 Oct:86:102107.,(\u75c7\u4f8b\u5831\u544a)<\/td>\r\n<\/tr>\r\n
2-12<\/td>\r\nJoji Nagasaki, Mitsutaka Nishimoto, Hideo Koh, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Kentaro Ido, Masatomo Kuno, Yosuke Makuuchi, Teruhito Takakuwa, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae: T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”,Blood Cancer J. 2024;14(1):79.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-13<\/td>\r\nYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino: The lymphocyte\/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients, Cancer Immunol Immunother. 2024;73(7):135.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-14<\/td>\r\nSoichiro Nakako, Hiroshi Okamura, Isao Yokota, Yukari Umemoto, Mirei Horiuchi, Kazuki Sakatoku, Kentaro Ido, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae: Dynamic Relapse Prediction by Peripheral Blood WT1mRNA after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasms, Transplant Cell Ther. 2024 Nov;30(11):1088.e1-1088.e12.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-15<\/td>\r\nYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, Yoshiyuki Onda, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka, Kensuke Ohta, Hirohiko Shibayama, Satoru Kosugi, Hideo Yagi, Satoshi Yoshihara, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino: The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients, Ann Hematol. 2024 Dec;103(12):5639-5649.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-16<\/td>\r\nTetsuya Hayashi, Yasuhiro Nakashima, Shinichi Takeda, Mitsutaka Nishimoto, Hiroshi Okamura, Teruhito Takakuwa, Masatomo Kuno, Yosuke Makuuchi, Kentaro Ido, Kazuki Sakatoku, Mirei Horiuchi, Hideo Koh, Mika Nakamae, Masayuki Hino, Hirohisa Nakamae: Posttransplantation cyclophosphamide mediates effective reconstitution of memory B cells after allogeneic hematopoietic cell transplantation, Eur J Haematol. 2024;113(5):651-663.,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n
2-17<\/td>\r\nKazutaka Sunami, Tomoaki Fujisaki, Toshinari Funaki, Michiko Ichii, Shigeki Ito, Morio Matsumoto, Koh-Ichi Oshima, Kazuhito Suzuki, Teruhito Takakuwa: Practical guidance on the clinical management of ocular adverse events associated with belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Recommendations from a , Jpn J Clin Oncol. 2025 Oct 6:hyaf148,(review)<\/td>\r\n<\/tr>\r\n
2-18<\/td>\r\n\u9ad9\u6851\u8f1d\u4eba\u3001\u5ca1\u5c71\u88d5\u4ecb\u3001\u592a\u7530\u5065\u4ecb\u3001\u4e2d\u524d\u535a\u4e45\u3001\u65e5\u91ce\u96c5\u4e4b\u3001\u5c71\u4e2d\u82f1\u6cbb: \u300c\u8840\u6db2\u75be\u60a3\uff08\u9020\u8840\u5668\u816b\u760d\uff09\u9023\u643a\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u300d\u3092\u6d3b\u7528\u3057\u305f\u62e0\u70b9\u75c5\u9662\u3068\u5730\u57df\u533b\u7642\u3068\u306e\u6a4b\u6e21\u3057,\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u8a8c. 2025;27(4):492-497,(\u7279\u96c6)<\/td>\r\n<\/tr>\r\n
2-19<\/td>\r\nYusuke Okayama, Teruhito Takakuwa, Yuji Shimura, Kazunori Imada, Satoru Kosugi, Masaaki Hotta, Shin-Ichi Fuchida, Hirokazu Tanaka, Nobuhiko Uoshima, Satoshi Yoshihara, Junya Kanda, Hirohiko Shibayama, Kentaro Fukushima, Kensuke Ohta, Hideo Yagi, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Naoki Hosen, Masayuki Hino, Junya Kuroda: Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum,Hematology. 2025 Dec;30(1):2496545,(\u539f\u8457)<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>","protected":false},"excerpt":{"rendered":"

2025\u5e74 1.\u5b66\u4f1a\u767a\u8868\u7b49 1-1 Yusuke Okayama : Complement involvements and issues in TA-TMA after allogeneic hematopoietic […]<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":1035,"menu_order":49,"comment_status":"closed","ping_status":"closed","template":"page-template_compo.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/pages\/10290"}],"collection":[{"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/comments?post=10290"}],"version-history":[{"count":5,"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/pages\/10290\/revisions"}],"predecessor-version":[{"id":11411,"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/pages\/10290\/revisions\/11411"}],"up":[{"embeddable":true,"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/pages\/1035"}],"wp:attachment":[{"href":"https:\/\/www.wakakoukai.or.jp\/daiichi\/wp-json\/wp\/v2\/media?parent=10290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}